Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
A Phase I, First-In-Human, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Study of TT-00920 in Healthy Subjects
Sponsor: TransThera Sciences (Nanjing), Inc.
Listed as NCT04364789, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by TransThera Sciences (Nanjing), Inc., it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TransThera Sciences (Nanjing), Inc.
For direct contact, visit the study record on ClinicalTrials.gov .